- OUTLOOK
Developing a cure for chronic hepatitis B requires a fresh approach
Access options
Nature 603, S49 (2022)
doi: https://doi.org/10.1038/d41586-022-00813-0
This article is part of Nature Outlook: Hepatitis B, an editorially independent supplement produced with the financial support of third parties. About this content.
References
Naggie, S. & Lok, A. S. Annu. Rev. Med. 72, 93–105 (2021).
Iannacone, M. & Guidotti, L. G. Nature Rev. Immunol. 22, 19–32 (2022).
Le Bert, N. et al. Gastroenterology 159, 652–664 (2020).
Aliabadi, E. et al. Gut https://doi.org/10.1136/gutjnl-2021-324646 (2021).
Fumagalli, V. et al. J. Exp. Med. 217, e20200298 (2020).
Benechet, A. P. et al. Nature 574, 200–205 (2019).
Michler, T. et al. Gastroenterology 158, 1762-1775 (2020).
Kennedy, P. T. F. et al. Gastroenterology 143, 637–645 (2012).
De Simone, G. et al. Immunity 54, 2089–2100 (2021).
Competing Interests
M.I. and L.G.G. are co-inventors on several patents (Patent appl. No. 20156716.1; Patent appl. No. 141758; Patent appl. No. 1907493.9; WO2020/234483; WO2020/030781; WO2020/016427; WO2020/016434) covering two potential interventions for the cure of chronic hepatitis B: first, the discovery of novel antivirals and, second, the idea of utilizing gene-therapy-based approaches to deliver a specific immunomodulator (IL-2) to the liver.